Statement: Less than 5 patients in the primary trial experienced Earache.
Primary_evidence: Adverse Events 1:   Total: 107/383 (27.94%)   Anaemia 4/383 (1.04%)   Febrile neutropenia 7/383 (1.83%)   Haemoytique anaemia 0/383 (0.00%)   Leukopenia 1/383 (0.26%)   Neutropenia 6/383 (1.57%)   Thrombocytopenia 2/383 (0.52%)   Anginal pectoris 1/383 (0.26%)   Cardiomyopathy 0/383 (0.00%)   Ear pain 0/383 (0.00%)   Abdominal distension 1/383 (0.26%)   Abdominal pain 6/383 (1.57%) Adverse Events 2:   Total: 85/383 (22.19%)   Anaemia 3/383 (0.78%)   Febrile neutropenia 2/383 (0.52%)   Haemoytique anaemia 0/383 (0.00%)   Leukopenia 0/383 (0.00%)   Neutropenia 1/383 (0.26%)   Thrombocytopenia 1/383 (0.26%)   Anginal pectoris 0/383 (0.00%)   Cardiomyopathy 1/383 (0.26%)   Ear pain 1/383 (0.26%)   Abdominal distension 0/383 (0.00%)   Abdominal pain 3/383 (0.78%)